Semaglutide (NN9535)

:Type 2 diabetes
:Phase 3

A once-weekly GLP-1 analogue intended to offer the clinical benefits of a GLP-1 analogue with less frequent injections.

Company announcements
Novo Nordisk to initiate phase 3 development of semaglutide, a once-weekly GLP-1 analogue (21 Jun 2012)
Novo Nordisk re-initiates phase 3 development of liraglutide for obesity (22 Jun 2010)
Read more company announcements

Press releases
Novo Nordisk invests DKK 380 million in its Kalundborg plant (06 May 2013)
Read more press releases

Scientific abstracts

No scientific abstracts matching the search criteria

You can search for more clinical trials on